Eton submits NDA to FDA for ET-400 hydrocortisone oral solution; approval expected Q1 2025

Eton Pharmaceuticals, Inc.

NDA submitted for ET-400, a proprietary patented hydrocortisone oral solution.
Company expects 10-month FDA review; potential approval and launch in Q1 2025.
Combined peak sales of ET-400 and Alkindi Sprinkle forecast to exceed $50M annually.
ET-400 has patent protection through 2043; additional patent applications under review.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.